KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Esperion Therapeutics (ESPR) Return on Equity (2019 - 2025)

Historic Return on Equity for Esperion Therapeutics (ESPR) over the last 8 years, with Q3 2025 value amounting to 0.24%.

  • Esperion Therapeutics' Return on Equity rose 1300.0% to 0.24% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.24%, marking a year-over-year increase of 1300.0%. This contributed to the annual value of 0.01% for FY2024, which is 5400.0% down from last year.
  • As of Q3 2025, Esperion Therapeutics' Return on Equity stood at 0.24%, which was up 1300.0% from 0.25% recorded in Q2 2025.
  • In the past 5 years, Esperion Therapeutics' Return on Equity registered a high of 1.13% during Q2 2021, and its lowest value of 0.01% during Q4 2024.
  • Its 5-year average for Return on Equity is 0.59%, with a median of 0.65% in 2023.
  • Examining YoY changes over the last 5 years, Esperion Therapeutics' Return on Equity showed a top increase of 60700bps in 2021 and a maximum decrease of -167500bps in 2021.
  • Quarter analysis of 5 years shows Esperion Therapeutics' Return on Equity stood at 0.98% in 2021, then fell by -22bps to 0.76% in 2022, then crashed by -35bps to 0.5% in 2023, then plummeted by -97bps to 0.01% in 2024, then surged by 1806bps to 0.24% in 2025.
  • Its Return on Equity was 0.24% in Q3 2025, compared to 0.25% in Q2 2025 and 0.26% in Q1 2025.